Stojan Arnerstål leads the team at Advokatfirman Vinge, which is well known for handling major, multijurisdictional IP disputes. The group often acts for private equity firms and global pharma companies, and Arnerstål is a key name for clients seeking advice on investments and acquisitions within the healthcare space. IP expert Håkan Borgenhäll regularly acts in patent and SPC disputes, with a strong focus on infringement actions. Christoffer Nordin and Malin Ohlin are key figures within the team with broad expertise in supply, manufacturing, and distribution agreements, and M&A.
Legal 500 Editorial commentary
Key clients
- Eli Lilly and Company
- Bridgepoint Growth
- Fidelio Capital
- Recipharm AB (publ)
- Atlas Antibodies AB
- Tamro AB
- Vimian Group AB (publ)
- Corline Biomedical AB (publ)
- Medivir AB (publ)
- Xspray Pharma AB (publ)
- Hansa Biopharma AB
- Calliditas Therapeutics AB (publ)
- Oncopeptides AB (publ)
- BioGaia AB (publ)
- Nanoform Finland Plc
- Medicover AB (publ)
- Järven Plast & Smide Aktiebolag
- Cinclus Pharma AB
- A3P Biomedical
- Healthcap
- Attgeno AB
- Biotage AB
- Thermo Fischer Scientific Inc
- Xvivo Perfusion AB
Work highlights
- Representing Merck Sharp & Dohme in a complex SPC dispute where KRKA challenges an SPC for Janumet. The case involves novel legal issues regarding dual SPCs for the same patent, with a pivotal referral to the EUCJ.
- Assisting Takeda Pharmaceutical Company Limited with a pending action against Sandoz regarding infringement in one of Takeda’s patents, covering a product to be used in the treatment of ADHD.
- Advising Thermo Fisher Scientific Inc. in connection with its acquisition of Olink Holding AB (publ).
Practice head
The lawyer(s) leading their teams.
Stojan Arnerstål